Clinical Trials | February 28, 2026
Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
The innovative eyedrop targets inflammation and pain following ocular surgery
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
